Response evaluation after single-fraction hemostatic radiotherapy in advanced cancer: a prospective study
Abstract
Background: Radiotherapy (RT) to the bleeding tumor is a potential alternative for achieving hemostasis in advanced or metastatic cancer, which is an oncologic emergency. The current study aimed to assess the effectiveness of single-fraction hemostatic RT for advanced cancer bleeding.
Materials and methods: This prospective observational study included patients with complaints of bleeding from their primary or secondary cancer sites. All patients received 6 Gray single-fraction hemostatic radiotherapy using conventional technique. The primary endpoint was to evaluate Subjective and Objective responses following radiotherapy, with regard to achieving hemostasis.
Results: Twenty-four patients with a median age of 45 years were included. The most common sites of bleeding were Gastrointestinal cancers (42%). The site of bleeding was the primary in 20 patients (83%), the rest had bleeding from metastatic fungating lymphadenopathy. The subjective and objective response rates to hemostatic RT were 87.5% each. The onset of response was within 24 hrs in 54.2% and at 2 weeks post-RT, there was complete control of bleeding in 45.8% of patients. The mean haemoglobin level of the study group improved by 0.9 gm/dL one week after hemostatic RT with reduced requirement of blood transfusions.
Conclusions: Hemostatic RT controlled bleeding in most patients irrespective of tumour site, histology and origin of bleeding. It can improve the general condition and hemoglobin levels in cancer patients, thereby making them fit for further treatments, which will likely result in prolongation of overall survival.
Keywords: advanced cancerbleedingsingle fractionhemostatic radiotherapyresponse evaluation
References
- Pereira J, Phan T. Management of bleeding in patients with advanced cancer. Oncologist. 2004; 9(5): 561–570.
- Lee YH, Lee JW, Jang HS. Palliative external beam radiotherapy for the treatment of tumor bleeding in inoperable advanced gastric cancer. BMC Cancer. 2017; 17(1): 541.
- Srinivasan V, Brown CH, Turner AG. A comparison of two radiotherapy regimens for the treatment of symptoms from advanced bladder cancer. Clin Oncol (R Coll Radiol). 1994; 6(1): 11–13.
- Biswal BM, Lal P, Rath GK, et al. Hemostatic radiotherapy in carcinoma of the uterine cervix. Int J Gynaecol Obstet. 1995; 50(3): 281–285.
- Din OS, Thanvi N, Ferguson CJ, et al. Palliative prostate radiotherapy for symptomatic advanced prostate cancer. Radiother Oncol. 2009; 93(2): 192–196.
- Lupattelli M, Tenti MV, Nucciarelli S, et al. Palliative short-course radiotherapy (RAPASH study) in patients with rectal cancer. Rep Pract Oncol Radiother. 2023; 28(3): 309–315.
- A Medical Research Council (MRC) randomised trial of palliative radiotherapy with two fractions or a single fraction in patients with inoperable non-small-cell lung cancer (NSCLC) and poor performance status. Medical Research Council Lung Cancer Working Party. Br J Cancer. 1992; 65(6): 934–941.
- Verheij M, Dewit L, Boomgaard M, et al. Ionizing Radiation Enhances Platelet Adhesion to the Extracellular Matrix of Human Endothelial Cells by an Increase in the Release of von Willebrand Factor. Radiat Res. 1994; 137(2): 202.
- Yarnold J, Brotons MCV. Pathogenetic mechanisms in radiation fibrosis. Radiother Oncol. 2010; 97(1): 149–161.
- Rodrigues G, Videtic GMM, Sur R, et al. Palliative thoracic radiotherapy in lung cancer: An American Society for Radiation Oncology evidence-based clinical practice guideline. Pract Radiat Oncol. 2011; 1(2): 60–71.
- Halperin EC EC, Wazer DE. (ed.). Perez and Brady’s principles and practice of radiation oncology. 6th ed. Wolters Kluwer/Lippincott Williams & Wilkins, Philadelphia 2013.
- Nomoto S, Akai T, Nomiyama H, et al. A retrospective study of the effectiveness of hemostatic radiotherapy with conventional fractionation in patients with advanced cancer. J Cancer Res Ther. 2015; 3(11): 124–128.
- Yan J, Milosevic M, Fyles A, et al. A hypofractionated radiotherapy regimen (0-7-21) for advanced gynaecological cancer patients. Clin Oncol (R Coll Radiol). 2011; 23(7): 476–481.
- Sapienza LG, Ning MS, Jhingran A, et al. Short-course palliative radiation therapy leads to excellent bleeding control: A single centre retrospective study. Clin Transl Radiat Oncol. 2019; 14: 40–46.
- Bezjak A, Dixon P, Brundage M, et al. Clinical Trials Group of the National Cancer Institute of Canada. Randomized phase III trial of single versus fractionated thoracic radiation in the palliation of patients with lung cancer (NCIC CTG SC.15). Int J Radiat Oncol Biol Phys. 2002; 54(3): 719–728.
- Duchesne GM, Bolger JJ, Griffiths GO, et al. A randomized trial of hypofractionated schedules of palliative radiotherapy in the management of bladder carcinoma: results of medical research council trial BA09. Int J Radiat Oncol Biol Phys. 2000; 47(2): 379–388.
- Rasool MT, Manzoor NA, Mustafa SA, et al. Hypofractionated radiotherapy as local hemostatic agent in advanced cancer. Indian J Palliat Care. 2011; 17(3): 219–221.
- Brundage MD, Bezjak A, Dixon P, et al. The role of palliative thoracic radiotherapy in non-small cell lung cancer. Can J Oncol. 1996; 6 Suppl 1: 25–32.
- Lee JAe, Lim DoH, Park W, et al. Radiation therapy for gastric cancer bleeding. Tumori. 2009; 95(6): 726–730.
- Cihoric N, Crowe S, Eychmüller S, et al. Clinically significant bleeding in incurable cancer patients: effectiveness of hemostatic radiotherapy. Radiat Oncol. 2012; 7: 132.
- Nieder C, Mannsåker B, Dalhaug A. Percent of remaining life on palliative radiation treatment: solely a function of fractionation? Rep Pract Oncol Radiother. 2023; 28(1): 47–53.